In a recent report CNN’s Paul La Monica notes “Healthcare stocks may keep your portfolio from needing a checkup.” He cites “Health care stocks often hold up well during tumultuous times. They are perceived to be stable companies that offer products and services people need even during a recession.”
In the report, UBS Global Wealth Management’s Solita Marcelli adds, “since 2003, global healthcare stocks have tended to outperform the broader market by more than 6% at times when the manufacturing sector is slumping.”
With that in mind, several healthcare opportunities on the nano-cap market are making news that could help them become great plays for investors seeking refuge in turbulent market conditions.
Wearable Health Solutions, Inc. (OTCMKTS: WHSI) is an established manufacturer of Personal Emergency Response Systems (“PERS”) devices in the rapidly expanding medical alarm device and eHealth sector. It provides innovative wearable healthcare products and services to dealers and distributors across the globe.
WHSI recently received a 20-cent price target from Litchfield Hills Research analyst, Theodore O’Neill. Currently, under 2 cents per share, a move closer to this target could provide investors significant returns.
WHSI is expected to launch its latest PERS device, the iHelp Max 4G™ in the summer of 2022. The device is a 4G cellular PERS unit with advanced features such as; fall detection, geo-fencing, AI utilizing Google Assistant and Alexa, notifications, daily check-ins, medication reminders and Remote Patient Monitoring (RPM).
Another factor making WHSI a company to watch is its planned uplisting. An uplisting would immediately open the company up to institutional and other high-net worth investors. When these investors see sell-side research with a 20 cent price target for a 2 cent stock, things could get interesting.
Start your research on WHSI immediately:https://topnewsguide.com/wearable-health-solutions-inc-whsi-profile/
Another medical device company, SPO Global Inc. (OTCMKTS: SPOM), recently released in depth information pertaining to the company’s medical devices. The company noted in the release “SPO Global Inc.’s medical devices include low frequency therapeutic instruments and intelligent Chinese medicine decocting machines, both of which have contributed to the company’s growing revenues.”
Company CEO Fengyou Lu said “We look forward to the completion of our projects in Shandong, Qingdao and other place. We will continue to update our shareholders with our progress and will strive to share some photos of our work, once the ongoing lockdowns in China have been lifted.”
CytoDyn Inc. (OTCMKTS: CYDY), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced a new, preclinical study in nonhuman primates that will evaluate the potential use in HIV of a gene therapy based on the experimental monoclonal antibody leronlimab.
The study is funded by a five-year grant of up to $5 million to OHSU from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH). The grant will fund the development and preclinical research of a single-injection gene therapy that codes for the leronlimab protein sequence and which will be delivered via an adeno-associated virus vector. The study will examine if this gene-therapy approach could provide the potential for “functional cure,” i.e., sustained viral suppression to people with HIV without requiring them to take medications for the rest of their lives.
Another biotech in the news, Northwest Biotherapeutics (OTCMKTS: NWBO), announced that the company submitted an application for license of the manufacturing facility in Sawston, UK for commercial manufacturing of cellular therapies to the Medicines and Healthcare Products Regulatory Agency (MHRA). The application builds upon the 3 licenses received for the Sawston facility in 2021.
NWBO is developing DCVax® personalized immune therapies for solid tumor cancers. The company requires further license from MHRA specifically for commercial manufacturing of cellular products. Application for a commercial license requires meeting even higher standards.
Preparations for this commercial license have included the creation of a further 50 standard operating procedures (SOPs) and policy and technical specification documents, validation of transport and shipping, and full validation and qualification of seven new pieces of equipment.
A dually-listed drug-delivery company, IntelGenx Technologies Corp. (TSX:IGX) (OTCMKTS:IGXT) announced that it has issued (i) 19,381,223 shares of common stock of the Company at a price of C$0.2812 in payment of the outstanding C$5,450,000 aggregate principal amount of the Company’s convertible unsecured subordinated debentures due June 30, 2022 and (ii) 573,684 Shares at a deemed price of C$0.38 per Share in payment of an aggregate of C$218,000 interest due on the Debentures as of June 30, 2022. (all above issuances are on the Toronto Stock Exchange)
IntelGenx’s film technologies include VersaFilm®, DisinteQ™, VetaFilm™ and transdermal VevaDerm™. IntelGenx’s product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.
Start your research on WHSI now:https://topnewsguide.com/wearable-health-solutions-inc-whsi-profile/
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quotes; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport ‘CGR’ is responsible for the production and distribution of this content. CGR is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. CGR authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. CGR is compensated three thousand dollars monthly via wire transfer by Wearable Health Solutions to produce and syndicate content related to WHSI. As part of that content, readers, subscribers, and website viewers, are expected to read the full disclaimers and financial disclosures statement that can be found on our website.